Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
NCT05177068
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
42
Enrollment
OTHER_GOV
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
fruquintinib + sintilimab + SOX
Sponsor
Henan Cancer Hospital